Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

ClinicalTrials.gov ID: NCT07214311

Public ClinicalTrials.gov record NCT07214311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)

Study identification

NCT ID: NCT07214311
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Peptilogics; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Prosthetic-joint Infection

Interventions

PLG0206 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2, 2026
Primary completion: Aug 31, 2028
Completion: Aug 31, 2028
Last update posted: May 13, 2026

2026 – 2028

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
Clinical Trial Site	Sarasota	Florida	34239	Recruiting
Clinical Trial Site	Tamarac	Florida	33321	Recruiting
Clinical Trial Site	Baltimore	Maryland	21215	Recruiting
Clinical Trial Site	Boston	Massachusetts	02120	Recruiting
Clinical Trial Site	Cincinnati	Ohio	45267	Recruiting
Clinical Trial Site	Columbus	Ohio	43210	Recruiting
Clinical Trial Site	Pittsburgh	Pennsylvania	15232	Recruiting
Clinical Trial Site	Edinburg	Texas	78539	Recruiting
Clinical Trial Site	Morgantown	West Virginia	26506	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07214311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 13, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07214311 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →